Clinical Trials
633 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
CaDAnCe-101
BeOne Medicines
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
MK-3475-04A
Merck Sharp & Dohme LLC
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
SURGE Therapeutics
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Washington University School of Medicine
SYRUS
AstraZeneca
NeoB-Cap1
Novartis
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Institutes of Health Clinical Center (CC)
NAPISTAR1-01
Tubulis GmbH
AFAN
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Everest Medicines (China) Co.,Ltd.
A Phase â… /â…¡a Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Hutchmed
TARLATEM
Centre Leon Berard
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Novartis
MK-3475-06B
Merck Sharp & Dohme LLC
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Children's Hospital of Philadelphia
RAINFOL-01
Genmab
EVEREST-2
A2 Biotherapeutics Inc.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
MK-5684-01A
Merck Sharp & Dohme LLC
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Fudan University
MK-3475-06C
Merck Sharp & Dohme LLC
STARLiT
Case Comprehensive Cancer Center
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
NEC Bio B.V
MK-5909-003
Merck Sharp & Dohme LLC
MK-3475-03C
Merck Sharp & Dohme LLC
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Dizal Pharmaceuticals
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
MK-6070-003
Merck Sharp & Dohme LLC
MK-3475-01F
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
MK-3475-G21
Merck Sharp & Dohme LLC
PARTHENON
AstraZeneca
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
National Institutes of Health Clinical Center (CC)
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
MORPHEUS-LIVER
Hoffmann-La Roche